Renal toxicity reports with zoledronic acid
- PDF / 122,931 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 33 Downloads / 190 Views
1
Renal toxicity reports with zoledronic acid Australia’s Adverse Drug Reactions Advisory Committee (ADRAC) has received 31 reports of renal impairment associated with zoledronic acid, from a total of 268 reports for this drug. The 31 reports involved either renal failure (n = 16) or renal impairment; zoledronic acid was the only suspected drug in 20 of the 31 reports. The age of patients described in the reports ranged between 44 and 88 years, with a median age of 63 years. Among approximately two thirds of the reports, the time to onset was between 1 and 3 months after starting treatment; recovery was, for the most part, unknown or unspecified. The indications for treatment with zoledronic acid included multiple myeloma (13 cases), breast cancer (5), prostate cancer (4), malignant melanoma, osteoporosis, plasmacytoma, osteomyelitis and bone metastases (1 case each). The delayed onset of renal toxicity in several cases may indicate that the adverse event was unrelated to the rate of infusion; however, many reports involved patients with pre-existing renal impairment. ADRAC has issued a reminder to prescribers to adhere to the instructions for use of zoledronic acid, and to be aware of risk factors for renal impairment. Renal impairment with zoledronic acid. Australian Adverse Drug Reactions 801052320 Bulletin 26: 18-19, No. 5, Oct 2007
0114-9954/10/1173-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 13 Oct 2007 No. 1173
Data Loading...
